Business Categories Reports Podcasts Events Awards Webinars
Contact My Account About

LB EQUITY INVESTS IN CBD PLATFORM STANDARD DOSE

Published February 3, 2019
Published February 3, 2019
Tiara Leitzman via Unsplash

LB Equity has taken a significant minority stake in Standard Dose from its new $50 million fund LB Equity Emerging Growth.

“LBE is targeting the massive opportunity available at the intersection of the rapidly growing cannabis industry and the many emerging brands within the skincare, beauty and related personal care sectors,” said Jay Lucas, Managing Partner of LB Equity. “With experienced executives from both the finance and beauty industries, LBE is perfectly positioned to leverage the transformational impact that these newly legalized cannabis-based products will have on the beauty industry.”

Standard Dose is a recently launched multi-brand online marketplace for CBD products. The current assortment offers a curated range of more than 60 ingestible and topical natural remedies for anxiety, pain, inflammation, detoxification, and skincare. Products sold on the platform is sampled and tested to ensure that it meets the highest standards of effectiveness, feel, and experience. Products are further validated through product lab test results, which are required for all brand partner submissions. All products meet legal standards and is made with industrial hemp that contains less than .3% THC.

“Our goal at Standard Dose is to facilitate an honest conversation about CBD and to help consumers gain clarity of an industry that, until now, has been confusing and unregulated,” said Anthony Saniger, Founder and CEO of Standard Dose. “We take the time to vet all of our products and share information so that consumers can choose CBD products with confidence. With the very recent legalization of CBD, we know that interest in the industry and its products will skyrocket. Standard Dose will be the go-to source for anyone interested in elevating their lifestyle by tapping into the natural health benefits of CBD products.”

×

2 Article(s) Remaining

Subscribe today for full access